Abstract PO4-03-07: The impact of chemotherapy relative dose intensity on pathological complete response in patients with triple negative breast cancer treated with neoadjuvant chemotherapy
Roberto Buonaiuto(Scuola Superiore Meridionale), Carmine De Angelis(Baylor College of Medicine), Pietro De Placido(University of Naples Federico II), Giuseppe Neola(University of Naples Federico II), Grazia Arpino(University of Naples Federico II), Giovanna Pecoraro(Federico II University Hospital), Valeria Forestieri(University of Naples Federico II), Mario Giuliano(Regione Campania), Sabino De Placido, Matteo Lambertini(Ospedale Policlinico San Martino), Erica Pietroluongo(University of Naples Federico II), Paola Trasacco(University of Naples Federico II), Federica P. Mangiacotti(Federico II University Hospital), Aldo Caltavituro(University of Naples Federico II)
Cited by 1
Related Papers
Cancer and fertility preservation: international recommendations from an expert meeting
|BMC Medicine|2016|779
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413